Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions

Blood eosinophil count and exacerbation risk in patients with COPD

Marjan Kerkhof, Samatha Sonnappa, Dirkje S. Postma, Guy Brusselle, Alvar Agustí, Antonio Anzueto, Rupert Jones, Alberto Papi, Ian Pavord, Emilio Pizzichini, Todor Popov, Nicolas Roche, Dermot Ryan, Mike Thomas, Claus Vogelmeier, Alison Chisholm, Daryl Freeman, Mona Bafadhel, Elizabeth V. Hillyer, David B. Price
European Respiratory Journal 2017 50: 1700761; DOI: 10.1183/13993003.00761-2017
Marjan Kerkhof
1Observational and Pragmatic Research Institute (OPRI), Singapore, Singapore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samatha Sonnappa
1Observational and Pragmatic Research Institute (OPRI), Singapore, Singapore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dirkje S. Postma
2Dept of Pulmonology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guy Brusselle
3Dept of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium
4Dept of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands
5Dept of Respiratory Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alvar Agustí
6Respiratory Institute, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
7Centro de Investigación Biomédica en red Enfermedades Respiratorias (CIBERES), Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonio Anzueto
8Division of Pulmonary Diseases and Critical Care Medicine, School of Medicine, The University of Texas Health Science Center, San Antonio, TX, USA
9Audie L. Murphy Memorial VA Hospital, South Texas Veterans Health Care System, San Antonio, TX, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rupert Jones
10Plymouth University Peninsula Schools of Medicine and Dentistry (PU PSMD), Plymouth University, Plymouth, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alberto Papi
11Dept of Medicine, University of Ferrara, Ferrara, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alberto Papi
Ian Pavord
12Respiratory Medicine Unit, Nuffield Dept of Medicine, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emilio Pizzichini
13Asthma Research Centre (NUPAIVA), University Hospital, Federal University of Santa Catarina, Florianópolis, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Todor Popov
14Clinic of Allergy and Asthma, Medical University Sofia, Sofia, Bulgaria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicolas Roche
15Unit EA2511 (Cystic Fibrosis and Chronic bronchopathy), Faculté de Médecine, Université Paris Descartes, Paris, France
16Hôpital Cochin, Assistance Publique Hôpitaux de Paris, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dermot Ryan
17Allergy and Respiratory Research Group, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mike Thomas
18Primary Care and Population Sciences, Aldermoor Health Centre, University of Southampton, Southampton, UK
19NIHR Southampton Respiratory Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claus Vogelmeier
20Dept of Medicine (Pulmonary and Critical Care Medicine), University Medical Center Giessen and Marburg, Philipps-University Marburg, Marburg, Germany
21German Center for Lung Research (DZL), Marburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alison Chisholm
22On behalf of the Respiratory Effectiveness Group, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daryl Freeman
23Mundesley Medical Centre, Mundesley, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mona Bafadhel
12Respiratory Medicine Unit, Nuffield Dept of Medicine, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth V. Hillyer
1Observational and Pragmatic Research Institute (OPRI), Singapore, Singapore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David B. Price
1Observational and Pragmatic Research Institute (OPRI), Singapore, Singapore
22On behalf of the Respiratory Effectiveness Group, Cambridge, UK
24Institute of Applied Health Sciences (Academic Primary Care), University of Aberdeen, Aberdeen, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for David B. Price
  • For correspondence: dprice@opri.sg
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Blood eosinophil count may serve as a biomarker of exacerbation risk in subgroups of patients with COPD http://ow.ly/6tm530cEAeO

To the Editor:

Exacerbations in chronic obstructive pulmonary disease (COPD) are major contributors to worsening lung function, impaired quality of life, emergency healthcare use and COPD-related mortality. COPD exacerbations are heterogeneous in terms of airway inflammation and aetiology. About 60% of COPD patients have blood eosinophil counts of ≥2%, which appears to be associated with an increased risk of exacerbations [1–3]. However, the association between blood eosinophil counts at stable disease and COPD exacerbations in the subsequent year is incompletely understood.

This historical follow-up study used longitudinal medical record data to evaluate blood eosinophil counts as a biomarker of exacerbation risk by assessing the association between blood eosinophil levels measured when COPD was stable and the exacerbation rate in the subsequent year, in a broad COPD population. We also investigated whether the association differed significantly between specific patient subgroups defined by smoking status, gender, disease severity (Global Initiative for Chronic Obstructive Lung Disease (GOLD) groups A–D), or treatment with inhaled corticosteroids (ICS). Data were extracted from March 1994 to February 2014 from the United Kingdom Optimum Patient Care Research Database.

We evaluated patient characteristics during one baseline year before the index date, defined as the date of most recent eosinophil count at stable COPD with ≥1 follow-up year available. Comorbidities included as potential confounding factors were defined as those ever recorded during the registration period, and assessed at index date. Eligible patients were aged ≥40 years, had a recorded COPD diagnosis, no other chronic respiratory disease, including no asthma-related code ever recorded, with at least one blood eosinophil count measured at stable disease (no COPD exacerbations within previous or subsequent 4 weeks). Other eligibility criteria were forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) <0.70 recorded within 5 years of index date, history of cigarette smoking (current and ex-smokers) and ≥1 year of data before and after index date. Eosinophil counts ranging from 0.05×109/L to <0.45×109/L were the reference category. Low counts were <0.05×109/L, and elevated counts ≥0.45×109/L, based on reference values applied in UK laboratories (0.04–0.40×109/L for adults) [4]. Analyses were adjusted for sex, age, body mass index, smoking status, therapy and history of comorbidities associated with eosinophil counts. COPD exacerbations were defined as: unscheduled hospital admission or emergency department attendance, and/or an acute course of oral corticosteroids, and/or antibiotics prescribed for a lower respiratory consultation. The association of blood eosinophil counts with subsequent exacerbations was analysed by estimating rate ratios (RRs) with 95% confidence intervals (CIs) using a quasi-Poisson regression model allowing for over-dispersion [5].

Of 64,847 identified patients with COPD, 8318 were eligible for inclusion in the study (56% men and mean±sd age of 70±10 years). Modified Medical Research Council (mMRC) scores were available for 6660 of these patients, for determining GOLD groups [6]. During the follow-up year, 40% of patients with reference eosinophil counts, 42% with elevated counts, and 43% with low counts experienced ≥1 COPD exacerbations, whereas 16%, 18%, and 17%, respectively, experienced ≥2 COPD exacerbations. Overall, patients with elevated blood eosinophil counts (8.9%) had a 13% higher exacerbation rate during the following year than patients in the reference group (87.7%). When investigating this association in different patient subgroups, we found a significant difference between ex-smokers and current smokers, with ex-smokers showing the higher exacerbation rate in patients with elevated blood eosinophil counts (table 1). We further compared exacerbation rates in four different patient subgroups, defined by smoking status and eosinophil counts. The reference group comprised ex-smokers with eosinophil counts in the reference range (0.05–0.45×109/L). Ex-smokers with elevated eosinophil counts had the highest exacerbation rate (RR 1.30; 95% CI 1.14–1.48); current smokers with elevated eosinophil counts had the lowest exacerbation rate (RR 0.89; 95% CI 0.73–1.08). We also found significant associations between elevated eosinophil counts and exacerbation rates in men (RR 1.21; 95% CI 1.06–1.38), patients treated with ICS (RR 1.17; 95% CI 1.02–1.35), and patients in GOLD group B (table 1). However, there was no significant effect modification by any of these characteristics. Further analysis of associations within the ex-smokers subgroup showed a significant increase in exacerbation rate with elevated eosinophil counts in male ex-smokers (n=2914; RR 1.40; 95% CI 1.20–1.64), ex-smokers treated with ICS (n=2545; RR 1.37; 95% CI 1.17–1.62) and ex-smokers in GOLD groups B–D (table 1). However, there was no significant effect modification by these characteristics. For COPD patients with low eosinophil counts (3.4%), the exacerbation rate was not significantly different from that in patients with reference counts (RR 1.06; 95% CI 0.89–1.27).

View this table:
  • View inline
  • View popup
TABLE 1

Rate ratios for the association between elevated blood eosinophil count and chronic obstructive pulmonary disease (COPD) exacerbation during follow-up year in the total population of COPD patients and in subgroups of patients defined by gender, smoking status, inhaled corticosteroid (ICS) therapy and Global Initiative for Chronic Obstructive Lung Disease (GOLD) group. The rate of COPD exacerbation in patients with an elevated eosinophil count (≥0.45×109 per L) relative to patients with a reference eosinophil count (0.05×109 per L to <0.45×109 per L) is shown for each subgroup. Differences between subgroups are tested by including an interaction term of elevated eosinophil count and the variable used to define the categories of the subgroup in a multiple regression model (e.g. interaction term of elevated eosinophil count (yes/no)×gender (male/female) had a p-value of 0.11).

We show that an elevated blood eosinophil count (≥0.45×109/L) in patients with stable COPD is associated with a higher exacerbation rate the following year. We observed that: (i) the increased exacerbation rate with elevated eosinophil count was restricted to ex-smokers; (ii) this association was significant both in male ex-smokers and in patients on ICS, but there was no interaction effect between sex or ICS and eosinophil count on exacerbation rate; (iii) patients with an elevated eosinophil count who were currently smoking showed the lowest exacerbation rate; and, (iv) there was no association between a low eosinophil count and COPD exacerbations.

A recent observational study (n=7225) reported that blood eosinophil counts >0.34×109/L are associated with increased risk of moderate and severe exacerbations in patients with spirometrically confirmed COPD [7]. However, the study did not investigate other patient characteristics that might affect the association between blood eosinophils and exacerbations. Our findings suggest that ex-smokers with stable COPD and elevated blood eosinophil counts may constitute a target population for more specific treatment of eosinophilic inflammation, because the increased risk was more pronounced in patients receiving ICS and this treatment does not appear to lower the blood eosinophil count [8]. Our finding of a higher percentage of men than women having elevated eosinophil counts is consistent with that of the Copenhagen study [7]. Gender-related differences in airway dimensions, structure, and function, together with variations in pathophysiological and, more specifically, inflammatory mechanisms elicited by tobacco smoking, may lead to differences in clinical manifestations of airway disease [9–11]. There is also some evidence that active tobacco smoking has a suppressive effect on eosinophils and inflammatory cells or cytokines [12], even in intermittent smokers [13].

We acknowledge that our study population is broader than the COPD population classically included in clinical trials. Real-life patients include a diverse spectrum of individuals with physician-diagnosed COPD. Many of these patients would not meet eligibility criteria for randomised controlled trials [14, 15], but are representative of the patients seen by clinicians. Study strengths include the large patient population drawn from geographically and socioeconomically diverse practices throughout the UK. In addition, 85% of our patients had recent spirometry results; GOLD groups could be defined in 80%; and 81% had blood count measurements. There are some limitations: i) although we used eosinophil counts at stable disease, we cannot exclude the possibility that specific indications may have influenced blood eosinophil levels, leading to an underestimation of the association between eosinophils and exacerbations; ii) we studied only the association with exacerbation rate in the subsequent year and did not assess whether there is a sustained increased risk over time; iii) we used the mMRC dyspnoea scale score to assign GOLD groups and results may have differed had we used the COPD assessment test [16].

To conclude, we have shown that elevated blood eosinophil counts may predict COPD exacerbation risk only in ex-smokers. This analytical strategy may eventually help in the targeting of therapy to specific patient subgroups to maximise benefit and minimise risk for individual patients.

Disclosures

Supplementary Material

A. Agustí ERJ-00761-2017_Agusti

A. Anzueto ERJ-00761-2017_Anzueto

M. Bafadhel ERJ-00761-2017_Bafadhel

G. Brusselle ERJ-00761-2017_Brusselle

D. Freeman ERJ-00761-2017_Freeman

E. V. Hillyer ERJ-00761-2017_Hillyer

R. Jones ERJ-00761-2017_Jones

M. Kerkhof ERJ-00761-2017_Kerkhof

A. Papi ERJ-00761-2017_Papi

I. Pavord ERJ-00761-2017_Pavord

D. S. Postma ERJ-00761-2017_Postma

D. B. Price ERJ-00761-2017_Price

N. Roche ERJ-00761-2017_Roche

D. Ryan ERJ-00761-2017_Ryan

S. Sonnappa ERJ-00761-2017_Sonnappa

M. Thomas ERJ-00761-2017_Thomas

C. Vogelmeier ERJ-00761-2017_Vogelmeier

Footnotes

  • Support statement: support was provided by the Respiratory Effectiveness Group (REG-RES1306). Funding information for this article has been deposited with the Crossref Funder Registry.

  • Conflict of interest: Disclosures can be found alongside this article at erj.ersjournals.com

  • Received November 14, 2016.
  • Accepted April 22, 2017.
  • Copyright ©ERS 2017

References

  1. ↵
    1. Bafadhel M,
    2. McKenna S,
    3. Terry S, et al.
    Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med 2012; 186: 48–55.
    OpenUrlCrossRefPubMedWeb of Science
    1. Pascoe S,
    2. Locantore N,
    3. Dransfield MT, et al.
    Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 2015; 3: 435–442.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Watz H,
    2. Tetzlaff K,
    3. Wouters EF, et al.
    Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med 2016; 4: 390–398.
    OpenUrlCrossRefPubMed
  3. ↵
    UK National Health Service NHS. Full Blood Count. www.pathology.leedsth.nhs.uk/pathology/ClinicalInfo/Haematology/FullBloodCount.aspx Date last updated: April 25, 2013. Date last accessed: June 06, 2017.
  4. ↵
    1. Ver Hoef JM,
    2. Boveng PL
    . Quasi-Poisson vs. negative binomial regression: how should we model overdispersed count data? Ecology 2007; 88: 2766–2772.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    Global strategy for the diagnosis, management and prevention of COPD. Global initiative for chronic obstructive lung disease (GOLD), 2016. http://goldcopd.org/global-strategy-diagnosis-management-prevention-copd-2016/ Date last accessed: June 06, 2017.
  6. ↵
    1. Vedel-Krogh S,
    2. Nielsen SF,
    3. Lange P, et al.
    Blood eosinophils and exacerbations in chronic obstructive pulmonary disease. The Copenhagen General Population Study. Am J Respir Crit Care Med 2016; 193: 965–974.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Barnes NC,
    2. Sharma R,
    3. Lettis S, et al.
    Blood eosinophils as a marker of response to inhaled corticosteroids in COPD. Eur Respir J 2016; 47: 1374–1382.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Becklake MR,
    2. Kauffmann F
    . Gender differences in airway behaviour over the human life span. Thorax 1999; 54: 1119–1138.
    OpenUrlFREE Full Text
    1. Faner R,
    2. Gonzalez N,
    3. Cruz T, et al.
    Systemic inflammatory response to smoking in chronic obstructive pulmonary disease: evidence of a gender effect. PLoS One 2014; 9: e97491.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Aryal S,
    2. Diaz-Guzman E,
    3. Mannino DM
    . Influence of sex on chronic obstructive pulmonary disease risk and treatment outcomes. Int J Chron Obstruct Pulmon Dis 2014; 9: 1145–1154.
    OpenUrlPubMed
  10. ↵
    1. van der Vaart H,
    2. Postma DS,
    3. Timens W, et al.
    Acute effects of cigarette smoke on inflammation and oxidative stress: a review. Thorax 2004; 59: 713–721.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. van der Vaart H,
    2. Postma DS,
    3. Timens W, et al.
    Acute effects of cigarette smoking on inflammation in healthy intermittent smokers. Respir Res 2005; 6: 22.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Travers J,
    2. Marsh S,
    3. Caldwell B, et al.
    External validity of randomized controlled trials in COPD. Respir Med 2007; 101: 1313–1320.
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    1. Halpin DM,
    2. Kerkhof M,
    3. Soriano JB, et al.
    Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy. Respir Res 2016; 17: 120.
    OpenUrl
  14. ↵
    1. Karloh M,
    2. Fleig MA,
    3. Maurici R, et al.
    The COPD assessment test: what do we know so far? A systematic review and meta-analysis about clinical outcomes prediction and classification of patients into GOLD stages. Chest 2016; 149: 413–425.
    OpenUrl
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 50 Issue 1 Table of Contents
European Respiratory Journal: 50 (1)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Blood eosinophil count and exacerbation risk in patients with COPD
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Blood eosinophil count and exacerbation risk in patients with COPD
Marjan Kerkhof, Samatha Sonnappa, Dirkje S. Postma, Guy Brusselle, Alvar Agustí, Antonio Anzueto, Rupert Jones, Alberto Papi, Ian Pavord, Emilio Pizzichini, Todor Popov, Nicolas Roche, Dermot Ryan, Mike Thomas, Claus Vogelmeier, Alison Chisholm, Daryl Freeman, Mona Bafadhel, Elizabeth V. Hillyer, David B. Price
European Respiratory Journal Jul 2017, 50 (1) 1700761; DOI: 10.1183/13993003.00761-2017

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Blood eosinophil count and exacerbation risk in patients with COPD
Marjan Kerkhof, Samatha Sonnappa, Dirkje S. Postma, Guy Brusselle, Alvar Agustí, Antonio Anzueto, Rupert Jones, Alberto Papi, Ian Pavord, Emilio Pizzichini, Todor Popov, Nicolas Roche, Dermot Ryan, Mike Thomas, Claus Vogelmeier, Alison Chisholm, Daryl Freeman, Mona Bafadhel, Elizabeth V. Hillyer, David B. Price
European Respiratory Journal Jul 2017, 50 (1) 1700761; DOI: 10.1183/13993003.00761-2017
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Disclosures
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • COPD and smoking
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Airway immune responses to COVID-19 vaccination in COPD patients
  • Wider access to rifapentine-based regimens is needed for TB care globally
  • Association between immunosuppressants and outcomes of COVID-19
Show more Agora

Research letters

  • Impact of depression and anxiety on exacerbation risk in bronchiectasis
  • Respiratory management of drowning-associated ARF
  • Mitochondrial DNA as biomarker of survival in RA-ILD
Show more Research letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society